Status: Not yet recruiting
SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma
This study is a randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Study of SYS6010 vs Investigator's Choice Single-Agent Chemotherapy in Locally Advanced/Metastatic/Recurrent ESCC Patients with Failure of At Least One Line of Systemic Therapy
Participants needed: 436
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.Updated: Feb 18, 2026
Eligibility criteria
Voluntarily sign the Informed Consent Form (ICF); [+8]
A past pathological diagnosis of esophageal cancer with adenocarcinoma, adenosqu... [+29]